[{"id":"355168ac-10dc-49c7-8139-2017041e1380","acronym":"","url":"https://clinicaltrials.gov/study/NCT05848999","created_at":"2023-05-08T15:04:06.615Z","updated_at":"2024-07-02T16:35:48.189Z","phase":"Phase 1","brief_title":"UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05848999","lead_sponsor":"Zhejiang University","biomarkers":" IL6 • MSLN • IL10","pipe":"","alterations":" ","tags":["IL6 • MSLN • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • UCLM802"],"overall_status":"Recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 04/27/2023","start_date":" 04/27/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-05-12"},{"id":"b002053e-8556-4fa5-82ed-3d2c05fde55e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05783089","created_at":"2023-03-24T16:04:11.215Z","updated_at":"2024-07-02T16:35:52.329Z","phase":"Phase 1","brief_title":"MSLN-targeted CAR-T Cells in Solid Tumors.","source_id_and_acronym":"NCT05783089","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" IL6 • MSLN • IL10","pipe":"","alterations":" ","tags":["IL6 • MSLN • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UCLM802"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2023-03-24"},{"id":"00f6bf90-3a08-455d-82d2-2ccde3366ae0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05775666","created_at":"2023-03-20T20:03:30.879Z","updated_at":"2024-07-02T16:35:52.909Z","phase":"Phase 1","brief_title":"UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05775666","lead_sponsor":"Peking University","biomarkers":" IL6 • MSLN • IL10","pipe":"","alterations":" ","tags":["IL6 • MSLN • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • UCLM802"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-03-20"},{"id":"62e81424-45a7-4f78-9a1d-1eea6fabca98","acronym":"","url":"https://clinicaltrials.gov/study/NCT05531708","created_at":"2022-09-08T14:56:13.081Z","updated_at":"2024-07-02T16:35:54.417Z","phase":"Phase 1","brief_title":"Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT05531708","lead_sponsor":"Shanghai Pudong Hospital","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • UCLM802"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/02/2021","start_date":" 04/02/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-03-01"},{"id":"c57218fe-9186-4e3a-b510-e014a45f68cf","acronym":"Amaretto","url":"https://clinicaltrials.gov/study/NCT04981691","created_at":"2021-07-29T14:53:07.374Z","updated_at":"2024-07-02T16:36:24.273Z","phase":"Phase 1","brief_title":"Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT04981691 - Amaretto","lead_sponsor":"Ruijin Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • MSLN CAR-T • UCLM802"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 01/09/2022","primary_completion_date":" 01/09/2022","study_txt":" Completion: 07/09/2022","study_completion_date":" 07/09/2022","last_update_posted":"2021-09-17"}]